- Home
- BRT vs BNTC Comparison
BRT vs BNTC Comparison
Compare BRT & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | BNTC |
|---|---|---|
| Founded | 1972 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.2M | 396.3M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BRT | BNTC |
|---|---|---|
| Price | $13.77 | $9.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $19.75 | ★ $27.67 |
| AVG Volume (30 Days) | 40.1K | ★ 124.1K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $9.26 |
| 52 Week High | $15.97 | $16.76 |
Technical Indicators
Market Signals| Indicator | BRT | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 27.48 |
| Support Level | $13.18 | N/A |
| Resistance Level | $14.87 | $13.49 |
| Average True Range (ATR) | 0.28 | 0.74 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 22.16 | 12.42 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.